Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Günter Emons

Showing results (11-20 of 112) with videos related to

Pageof 12
Sort By:
Deutsches Arzteblatt International|September 10, 2011
The diagnosis and treatment of endometrial cancer: progress and controversiesDominik Denschlag, Uwe Ulrich, Günter Emons
Breast Cancer Research and Treatment|February 1, 2012
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapyRainer Girgert, Günter Emons, Carsten Gründker
Frontiers in Oncology|April 18, 2020
Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and DeathMatthias Läsche, Günter Emons, Carsten Gründker
Frontiers in Endocrinology|January 29, 2019
Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPERRainer Girgert, Günter Emons, Carsten Gründker
Cancers|September 10, 2020
Tamoxifen and Endometrial Cancer: A Janus-Headed DrugGünter Emons, Alexander Mustea, Clemens Tempfer
Trends in Endocrinology and Metabolism: TEM|June 2, 2005
Black cohosh: just another phytoestrogen?Volker Viereck, Günter Emons, Wolfgang Wuttke
Oncology Reports|December 14, 2016
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinibRainer Girgert, Günter Emons, Carsten Gründker
Advances in Experimental Medicine and Biology|July 22, 2008
Hormonal heterogeneity of endometrial cancerCarsten Gründker, Andreas R Günthert, Günter Emons
Molecular Cancer Therapeutics|February 17, 2005
Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancersCarsten Gründker, Abdohamid Huschmand Nia, Günter Emons
Bioelectromagnetics|November 3, 2009
Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fieldsRainer Girgert, Volker Hanf, Günter Emons, et al.
Pageof 12

Showing results (11-20 of 112) with videos related to

Sort By:
Pageof 12
Deutsches Arzteblatt International|September 10, 2011
The diagnosis and treatment of endometrial cancer: progress and controversiesDominik Denschlag, Uwe Ulrich, Günter Emons
Breast Cancer Research and Treatment|February 1, 2012
Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapyRainer Girgert, Günter Emons, Carsten Gründker
Frontiers in Oncology|April 18, 2020
Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and DeathMatthias Läsche, Günter Emons, Carsten Gründker
Frontiers in Endocrinology|January 29, 2019
Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPERRainer Girgert, Günter Emons, Carsten Gründker
Cancers|September 10, 2020
Tamoxifen and Endometrial Cancer: A Janus-Headed DrugGünter Emons, Alexander Mustea, Clemens Tempfer
Trends in Endocrinology and Metabolism: TEM|June 2, 2005
Black cohosh: just another phytoestrogen?Volker Viereck, Günter Emons, Wolfgang Wuttke
Oncology Reports|December 14, 2016
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinibRainer Girgert, Günter Emons, Carsten Gründker
Advances in Experimental Medicine and Biology|July 22, 2008
Hormonal heterogeneity of endometrial cancerCarsten Gründker, Andreas R Günthert, Günter Emons
Molecular Cancer Therapeutics|February 17, 2005
Gonadotropin-releasing hormone receptor-targeted gene therapy of gynecologic cancersCarsten Gründker, Abdohamid Huschmand Nia, Günter Emons
Bioelectromagnetics|November 3, 2009
Signal transduction of the melatonin receptor MT1 is disrupted in breast cancer cells by electromagnetic fieldsRainer Girgert, Volker Hanf, Günter Emons, et al.
Pageof 12